- Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?14¢14%
The FDA’s Pharmacy Compounding Advisory Committee voted narrowly in July 2026 to recommend BPC-157 for the 503A Bulks List despite staff findings of insufficient safety and efficacy data, creating momentum for potential interim relief. BPC-157 was removed from Category 2 enforcement-risk status in April 2026 after nominators withdrew, but it has not entered Category 1 or gained compounding authorization. In mid-October 2026, HHS and FDA submitted an interim access policy covering certain peptides including BPC-157 to the White House Office of Management and Budget for review, which could establish temporary enforcement discretion while permanent rulemaking proceeds. Any final shift requires formal FDA action and notice-and-comment procedures that typically span months; traders are monitoring the outcome of the current White House review and subsequent agency steps for signals on timeline.
Rules
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.